Project Grant R43AR085490
Award Date 9/16/25
Completion Date 8/31/26
Dollars Obligated $314K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award of $646,506 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting the development of dual-action nanoparticle-loaded microparticles for the treatment of osteoarthritis (OA). The research aims to create innovative nanoparticle-based therapeutics that can stimulate the anabolic activity of chondroprogenitors to enhance cartilage...
- This federal Project Grant award of $1,950,412.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), to Wake Forest University Health Sciences. The funding supports research to define how the IRE1A-XBP1-NUPR1 signaling axis in immune cells and chondrocytes contributes to synovial inflammation, cartilage damage, and osteoarthritis pain. The...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $2,017,972 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Washington University in Missouri. The grant, with a performance period from September 10, 2025 to August 31, 2028, will fund research on the safety and efficacy of intra-articular corticosteroid injections for treating symptomatic osteoarthritis. Key objectives include investigating the...
- This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $312,323 Project Grant to Knoubis Bio Inc. under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports the development of a novel bispecific biologic therapy for rheumatoid arthritis (RA) that targets the transmembrane tyrosine phosphatase PTPRS. The key activities under this Phase I project include conducting pharmacokinetic studies in mice...
- This $314,362 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) aims to develop and commercialize a novel therapy for arthrofibrosis (AF), a condition characterized by excessive buildup of fibrous collagen in joint structures. The research program will evaluate 10 different small molecule drug candidates from Novomedix LLC, a woman-owned small business in San Diego, to assess...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $540,974 to Duke University to conduct research on Janus kinase (JAK) signaling in post-traumatic osteoarthritis (PTOA). The research aims to identify the specific JAK molecules that mediate the cartilage degradation and pain associated with PTOA, and to test selective JAK...
- The University of Massachusetts Medical School was awarded a $1,066,302 project grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant will fund the creation of a biomedical knowledgebase to promote and facilitate the use of the Osteoarthritis Initiative (OAI), one of the most extensive osteoarthritis research cohorts. The knowledgebase will...
- This Project Grant award, valued at $196,460.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The purpose of the award is to test a miniature knee joint system as a new tool to study the role of neuro-immune interactions in osteoarthritis pain. The University of Pittsburgh, the awardee, will use this novel microphysiological system with cartilage,...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on defining the role of the NOTCH2 gene in articular inflammation and the development of osteoarthritis. The $404,187 grant, awarded on May 14, 2025, will enable researchers at the University of Connecticut Health Center to utilize a conditional NOTCH2 mouse model to: 1) determine...